Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce the font size Increase the font size  
 
 

Research & Development

Contact Us

Sanofi

Sanofi House,
CTS No.117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400072

Tel no. (022) 28032000
Fax no.(022) 28032846

Content :

Partnerships

Sanofi is developing a partnership strategy, particularly in biotechnologies and biotherapy, forging strategic partnerships around the world with recognized experts to achieve faster, better progress towards new therapeutic solutions.

 

Innovation, the core of Sanofi strategy, starts with creativity, curiosity and open-mindedness.
Science helps build knowledge and innovation, daily reminder that partnerships are a foundation for progress. Future successes in our industry will come from building on shared ideas. Team spirit has always been vital to medicine. From top management and throughout our organization we are committed to ensuring that external breakthrough discoveries become successful innovative products.

As a global healthcare company, we are looking for all public and private partnerships that will open a door to new solutions for better health. We want to remain at the cutting edge in many fields, including biotherapy, stem cells and regenerative medicine or simply expand our portfolio with services or technologies that are not currently among our key areas of research. This will enable us not only to maintain our leadership in our current fields of therapeutic expertise, but also to seek out products and therapies in areas which our own programs have not yet explored.

  • For several years, Sanofi has been working with Regeneron to develop and commercialize human therapeutic antibodies.
  • Through a strategic collaboration with Dyax, Sanofi has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody SAR161578.
  • In October 2009, Sanofi announced the acquisition of Fovea, a French research and development biopharmaceutical company, focused on ocular diseases, with a unique technology platform and several discovery programs dedicated to back of the eye diseases.
  • In vaccines, Sanofi Pasteur recently concluded a partnership with the Dutch firm Crucell to develop and commercialize a new generation of monoclonal antibodies to fight rabies.

Demand for new and existing vaccines is estimated to double by year 2016. Sanofi Pasteur has developed partnership opportunities to boost its development and production of human vaccines for both prophylactic and therapeutic purposes. Current areas of Sanofi Pasteur vaccine development include vaccines to fight infectious diseases, cancer and chronic diseases.

Updated March 19, 2010

Module :

Corporate information

Corporate information